Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke

Neurosciences

Volumn 12, Issue 1, 2007, Pages 25-30

  Domaç, Füsun M ^a   Somay, Göksel ^a   Misirli, Handan ^a   Erenoglu, Nuri Y ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; RANKIN SCALE; RISK FACTOR;

EID: 34250020492     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004; 17: 1-5.
2. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. Early increases in TNF-α, IL-6, and IL-1 levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996; 206: 149-152.
3. Clark WM. Cytokines and reperfusion injury. Neurology 1997; 49: 10-14.
4. Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B, et al. Increased cytokine release from peripheral blood count in acute stroke. J Cereb Blood Flow Metab 1999; 19: 1004-1009.
5. Acalovski D, Wiest T, Hartmann M. Multiple levels of regulation of the Interleukin-6 system in stroke. Stroke 2003; 34: 1864-1870.
6. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4: 2.
7. Dawson DA, Martin D, Hallenbeck JM. Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996; 218: 41-44.
8. Yin L, Ohtaki H, Nakamachi T, Dohi K, Iwai Y, Funahashi H, et al. Expression of tumor necrosis factor alpha follow transient cerebral ischemia. Acta Neurochir Suppl 2003; 86: 93-96.
9. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, et al. Tumor necrosis factor in ischemic neurons. Stroke 1994; 25: 1481-1488.
10. Hallenbeck JM. Cytokines, macrophages, and leukocytes in brain ischemia. Neurology 1997; 49: 5-9.
11. Chung IY, Benveniste EN. Tumour necrosis factor-α production by astrocytes. Induction by lipopolysaccharide, IFN-gamma and IL-1 beta. J Immunol 1990; 144: 2999-3007
12. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.
13. Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 1992; 263: 1-16.
14. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor and S-100 protein in patients with acute stroke. Stroke 1996; 27: 1553-1557.
15. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, et al. Early intrathecal production of Interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-1398.
16. Legos JJ, Whitmore RR, Erhardt JA, Parsons AA, Tuma RF, Barone FC. Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett 2000; 282: 189-192.
17. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
18. Perini F, Mora M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and proinflammatory interleukins in acute ischemic stroke patients. Neurol Sci 2001; 22: 289-296.
19. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A. Inflammation-mediated damage in progressing lacunar infarctions. A potential therapeutic target. Stroke 2002; 33: 982-987.
20. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of Interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-47.
21. Youker K, Smith CW, Anderson DC, Miller D. Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collect during ischemia and reperfusion. J Clin Invest 1992; 89: 602-609.
22. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberg JR. Interleukin-6 and Interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995; 37: 800-804.
23. Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763-1771.
24. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4: 250-255.
25. Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci 1999; 162: 185-188.
26. Boysen G, Christensen H. Early Stroke: A dynamic process. Stroke 2001; 32: 2423-2425.
27. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, et al. Acute-phase proteins before cerebral ischemia in stroke-prone rats. Stroke 2001; 32: 753-760.
28. Engstörm G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002; 33: 2744-2749.
29. Warlow CP, Dennis MS, Van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, et al, editors. In: Stroke: A practical guide to management. Oxford, UK: Blackwell Scientific Productions; 1996. p. 181-191.
30. Sairanen T, Carpen O, Karjalainen ML. Evolution of cerebral tumor necrosis factor-α production during human ischemic stroke. Stroke 2001; 32: 1750.
31. Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumour necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2000; 20: 53-65.
32. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996; 27: 1734-1738.
33. Romera C, Hurtado O, Botella SH. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM 17- Tumor Necrosis Factor-α Pathway. J Neurosci 2004; 24: 1350-1357.
34. Ishibashi N, Prokopenko O, Reuhl KR, Mirochnitchenko O. Inflammatory response and glutathion peroxidase in a model of stroke. J Immunol 2002; 168: 1926-1933.
35. Akassoglou K, Probert I, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron -specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997; 158: 438-445.
36. Loddick SA, Rotwell NJ. Mechanisms of tumor necrosis factor-α action on neurodegeneration: interaction with insulin-like growth factor-1. Proc Natl Acad Sci USA 1999; 96: 9449-9451.
37. Feuerstein G, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-α. Cerebrovasc Brain Metab Rev 1994; 6: 341-360.
38. Castillo J, Moro MA, Blanco M. The release of Tumor Necrosis Factor-α is associated with ischemic tolerance in human stroke. Ann Neurol 2003; 54: 811-819.
39. Aloisi F, Care A, Borselino G. Production of hemolyphopoietic cytokines (IL-6,IL-8, colony-stimulating factors) by normal astrocytes in response to IL-1 beta and tumor necrosis factor-α. J Immunol 1992; 149: 2358-2366.
40. Szaflarski J, Burtrum D, Silverstein FS. Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke 1995; 26: 1093-1100.
41. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143: 3517-3523.
42. Ferrarese C, Mascarucci P, Zoia C. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19: 1004-1009.
43. Zaremba J, Losy J. The levels of TNF-alpha in cerebrospinal fluid and serum do not correlate with the counts of the white blood cells in acute phase of ischaemic stroke. Folia Morphol (Warsz) 2001; 60: 91-97.
44. Intiso D, Zarrelli MM, Lagioia G. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24: 390-396.
45. Wu S, Liu S, Zhao R. Effect of longshoudan on serum tumor necrosis factor and circulating endothelial cell levels in acute cerebral infarction patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000; 20: 91-93.
46. Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother 2001; 55: 258-263.
47. Montaner J, Rovira A, Molina CA. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003; 23: 1403-1407.
48. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69-78.
49. Tarkowski E, Rosengren L, Blomstrand C. Intrathecal release of pro-antiinflammatory cytokines during stroke. Clin Exp Immunol 1997; 110: 492-499.
50. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001; 104: 288-295.
51. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998; 11: 45-49.
52. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow 1999: 19; 819-834.
53. Wang MJ, Huang HM, Hsieh SJ, Jeng KC, Kuo JS. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 2001; 112: 28-34.
54. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 1991; 22: 877-883.
55. Vila N, Reverter JC, Yague J, Chamorro A. Interaction between interleukin-6 and the natural anticoagulant system in acute stroke. J Interferon Cytokine Res 2000; 20: 325-329.
56. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke. An independent prognostic factor. Stroke 2001; 32: 917-924.
57. Honczarenko K, Torbus Lisiecka B, Ousuch Z. Fibrinogen and lipids: Associated risk factors for ischemic cerebral stroke. Neurol Neurochir Pol 1972; 33: 557-565.
58. Fisher M, Meiselman HJ. Hemorheological factors in cerebral ischemia. Stroke 1991; 22: 1164-1169.